019170.KS
Shin Poong Pharm.Co.,Ltd. [019170.KS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
019170.KS Stock Summary
Top 10 Correlated ETFs
019170.KS
Top 10 Correlated Stocks
019170.KS
In the News
019170.KS Financial details
Company Rating
Buy
Market Cap
653.83B
Income
-41.06B
Revenue
209.41B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
828
Optionable
No
Shortable
Yes
Earnings
14 Nov 2023
P/E
-16
Forward P/E
-
PEG
-0.6
P/S
3.1
P/B
2.15
P/C
-
P/FCF
-15.51
Quick Ratio
-
Current Ratio
2.97
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-820.41
EPS next Y
-
EPS next Q
-
EPS this Y
220.09%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
2.24%
Revenue Q/Q
-7.5%
EPS Q/Q
-10.76%
-
-
-
-
SMA20
2.27%
SMA50
-19.19%
SMA100
-16.36%
Inst Own
-
Inst Trans
-
ROA
-11%
ROE
-13%
ROC
-0.13%
Gross Margin
40%
Oper. Margin
-20%
Profit Margin
-20%
Payout
-
Shs Outstand
49.27M
Shs Float
34.01M
-
-
-
-
Target Price
-
52W Range
9560.0-24000.0
52W High
-45.38%
52W Low
+37.13%
RSI
50.79
Rel Volume
0.43
Avg Volume
286.77K
Volume
122.56K
Perf Week
3.55%
Perf Month
10.63%
Perf Quarter
-21.12%
Perf Half Y
-23.65%
-
-
-
-
Beta
0.895
-
-
Volatility
360.91%, 531.88%
Prev Close
-1.21%
Price
13110
Change
-2.89%
019170.KS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.74K | 3.81K | 3.95K | 3.68K | 4.25K | |
| Net income per share | 56 | 107 | 100 | -223.88 | -716.62 | |
| Operating cash flow per share | 640.22 | 388.91 | 401.02 | -1.38K | -536.7 | |
| Free cash flow per share | 603.48 | 103.92 | 338.66 | -1.49K | -663.12 | |
| Cash per share | 1.33K | 1.33K | 3.81K | 1.8K | 1.13K | |
| Book value per share | 4.12K | 4.18K | 7.46K | 6.87K | 6.69K | |
| Tangible book value per share | 4K | 4.02K | 7.32K | 6.71K | 6.57K | |
| Share holders equity per share | 4.12K | 4.18K | 7.46K | 6.87K | 6.69K | |
| Interest debt per share | 2.23K | 2.22K | 94.55 | 26.86 | 56 | |
| Market cap | 313.42B | 360.23B | 6203.48B | 1644.87B | 1010.06B | |
| Enterprise value | 383.69B | 443.35B | 6149.46B | 1618.42B | 970.29B | |
| P/E ratio | 111.79 | 67.66 | 1.24K | -142.71 | -28.61 | |
| Price to sales ratio | 1.67 | 1.9 | 31.37 | 8.69 | 4.83 | |
| POCF ratio | 9.78 | 18.62 | 309.21 | -23.16 | -38.2 | |
| PFCF ratio | 10.37 | 69.67 | 366.15 | -21.46 | -30.91 | |
| P/B Ratio | 1.52 | 1.73 | 16.61 | 4.65 | 3.06 | |
| PTB ratio | 1.52 | 1.73 | 16.61 | 4.65 | 3.06 | |
| EV to sales | 2.05 | 2.34 | 31.1 | 8.55 | 4.64 | |
| Enterprise value over EBITDA | 17.4 | 21.38 | 261.05 | 445.8 | 12.44 | |
| EV to operating cash flow | 11.97 | 22.91 | 306.52 | -22.79 | -36.69 | |
| EV to free cash flow | 12.7 | 85.74 | 362.97 | -21.12 | -29.7 | |
| Earnings yield | 0.01 | 0.01 | 0 | -0.01 | -0.03 | |
| Free cash flow yield | 0.1 | 0.01 | 0 | -0.05 | -0.03 | |
| Debt to equity | 0.52 | 0.51 | 0 | 0 | 0.01 | |
| Debt to assets | 0.28 | 0.28 | 0 | 0 | 0.01 | |
| Net debt to EBITDA | 3.19 | 4.01 | -2.29 | -7.29 | -0.51 | |
| Current ratio | 1.54 | 1.64 | 3.99 | 7.96 | 7.23 | |
| Interest coverage | 2.5 | 2.05 | 3.85 | -44.76 | -40.94 | |
| Income quality | 11.39 | 3.59 | 3.98 | 6.16 | 0.75 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | -0.45 | 0 | |
| Sales general and administrative to revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.54 | |
| Research and developement to revenue | 0.03 | 0.03 | 0.03 | 0.09 | 0.15 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.06 | -0.73 | -0.16 | 0.08 | 0.24 | |
| Capex to revenue | -0.01 | -0.07 | -0.02 | -0.03 | -0.03 | |
| Capex to depreciation | -0.16 | -1.15 | -0.26 | -0.44 | -0.49 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.28K | 3.17K | 4.1K | 5.88K | 10.39K | |
| ROIC | 0.02 | 0.02 | 0.02 | -0.03 | -0.1 | |
| Return on tangible assets | 0.01 | 0.01 | 0.01 | -0.03 | -0.1 | |
| Graham Net | -6.85 | -60.76 | 3.43K | 2.78K | 2.41K | |
| Working capital | 78.44B | 85.24B | 249.47B | 198.68B | 169.37B | |
| Tangible asset value | 200.36B | 200.21B | 366.27B | 345.59B | 323.83B | |
| Net current asset value | 51.14B | 48.21B | 219.99B | 189.21B | 165.76B | |
| Invested capital | 0.52 | 0.51 | 0 | 0 | 0.01 | |
| Average receivables | 120.4B | 107.57B | 97.68B | 89.31B | 90B | |
| Average payables | 23.17B | 19.77B | 13.58B | 10.42B | 11.74B | |
| Average inventory | 45.93B | 46.98B | 49.06B | 48.4B | 47.3B | |
| Days sales outstanding | 218.34 | 198.25 | 170.38 | 166.49 | 163.38 | |
| Days payables outstanding | 69.28 | 59.07 | 26.46 | 39.36 | 31.77 | |
| Days of inventory on hand | 147.1 | 157.61 | 147.8 | 155.68 | 130.35 | |
| Receivables turnover | 1.67 | 1.84 | 2.14 | 2.19 | 2.23 | |
| Payables turnover | 5.27 | 6.18 | 13.79 | 9.27 | 11.49 | |
| Inventory turnover | 2.48 | 2.32 | 2.47 | 2.34 | 2.8 | |
| ROE | 0.01 | 0.03 | 0.01 | -0.03 | -0.11 | |
| Capex per share | -36.75 | -284.99 | -62.37 | -109.06 | -126.42 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.08K | 1.19K | 981.68 | 1.04K | 0 | |
| Net income per share | -188.78 | -344.96 | -142.38 | -176 | 0 | |
| Operating cash flow per share | -132.02 | -378.71 | -85.38 | 4.07 | 0 | |
| Free cash flow per share | -156.37 | -398.95 | -152.11 | -136.79 | 0 | |
| Cash per share | 1.58K | 1.13K | 1.62K | 1.42K | 0 | |
| Book value per share | 6.86K | 6.69K | 6.57K | 6.15K | 0 | |
| Tangible book value per share | 6.74K | 6.57K | 6.45K | 6.05K | 0 | |
| Share holders equity per share | 6.86K | 6.69K | 6.57K | 6.15K | 0 | |
| Interest debt per share | 47.07 | 116.38 | 583.72 | 622.72 | 0 | |
| Market cap | 980.49B | 1010.06B | 887.37B | 812.91B | 0 | |
| Enterprise value | 944.42B | 970.29B | 869.8B | 796.16B | 0 | |
| P/E ratio | -26.35 | -14.86 | -31.62 | -22.59 | 0 | |
| Price to sales ratio | 18.37 | 17.18 | 18.35 | 15.3 | 0 | |
| POCF ratio | -150.74 | -54.13 | -210.93 | 3.9K | 0 | |
| PFCF ratio | -127.26 | -51.39 | -118.4 | -116.24 | 0 | |
| P/B Ratio | 2.9 | 3.06 | 2.74 | 2.59 | 0 | |
| PTB ratio | 2.9 | 3.06 | 2.74 | 2.59 | 0 | |
| EV to sales | 17.69 | 16.5 | 17.98 | 14.99 | 0 | |
| Enterprise value over EBITDA | -103.65 | 9.78 | 45.42 | 36.35 | 0 | |
| EV to operating cash flow | -145.19 | -52 | -206.75 | 3.82K | 0 | |
| EV to free cash flow | -122.58 | -49.36 | -116.06 | -113.84 | 0 | |
| Earnings yield | -0.01 | -0.02 | -0.01 | -0.01 | 0 | |
| Free cash flow yield | -0.01 | -0.02 | -0.01 | -0.01 | 0 | |
| Debt to equity | 0.01 | 0.01 | 0.1 | 0.1 | 0 | |
| Debt to assets | 0.01 | 0.01 | 0.08 | 0.08 | 0 | |
| Net debt to EBITDA | 3.96 | -0.4 | -0.92 | -0.77 | 0 | |
| Current ratio | 7.22 | 7.23 | 3.75 | 3.55 | 2.97 | |
| Interest coverage | -815.61 | -2.54 | 4.08 | -20.57 | 0 | |
| Income quality | 0.77 | 1.1 | 0.6 | -0.02 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.03 | 1.82 | 0.64 | 0.59 | 0.62 | |
| Research and developement to revenue | 0.24 | 0.19 | 0.21 | 0.16 | 0 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0 | |
| Capex to operating cash flow | 0.18 | 0.05 | 0.78 | -34.59 | 0 | |
| Capex to revenue | -0.02 | -0.02 | -0.07 | -0.14 | 0 | |
| Capex to depreciation | -0.37 | -0.32 | -1.19 | -2.32 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 5.4K | 7.21K | 4.59K | 4.94K | 0 | |
| ROIC | -0.03 | -0.04 | -0.03 | -0.03 | -0.03 | |
| Return on tangible assets | -0.02 | -0.05 | -0.02 | -0.02 | -0.02 | |
| Graham Net | 2.6K | 2.41K | 2.26K | 1.97K | 0 | |
| Working capital | 185.65B | 169.37B | 163.38B | 150.42B | 142.31B | |
| Tangible asset value | 331.87B | 323.83B | 317.98B | 309.32B | 307.41B | |
| Net current asset value | 174.33B | 165.76B | 159.97B | 147.73B | 138.68B | |
| Invested capital | 0.01 | 0.01 | 0.1 | 0.1 | 0 | |
| Average receivables | 87.92B | 92.03B | 92.32B | 88.3B | 42.81B | |
| Average payables | 10.57B | 10.22B | 11.71B | 12.45B | 6.45B | |
| Average inventory | 50.18B | 47.15B | 49.39B | 51.47B | 25.53B | |
| Days sales outstanding | 152.38 | 143.41 | 169.26 | 145.09 | 0 | |
| Days payables outstanding | 23.74 | 28.23 | 36.97 | 37.17 | 0 | |
| Days of inventory on hand | 124.89 | 115.82 | 159.83 | 147.21 | 0 | |
| Receivables turnover | 0.59 | 0.63 | 0.53 | 0.62 | 0 | |
| Payables turnover | 3.79 | 3.19 | 2.43 | 2.42 | 0 | |
| Inventory turnover | 0.72 | 0.78 | 0.56 | 0.61 | 0 | |
| ROE | -0.03 | -0.05 | -0.02 | -0.03 | -0.03 | |
| Capex per share | -24.36 | -20.24 | -66.72 | -140.86 | 0 |
019170.KS Frequently Asked Questions
What is Shin Poong Pharm.Co.,Ltd. stock symbol ?
Shin Poong Pharm.Co.,Ltd. is a KR stock and trading under the symbol 019170.KS
What is Shin Poong Pharm.Co.,Ltd. stock quote today ?
Shin Poong Pharm.Co.,Ltd. stock price is $13110 today.
Is Shin Poong Pharm.Co.,Ltd. stock public?
Yes, Shin Poong Pharm.Co.,Ltd. is a publicly traded company.
Company Profile
- Volume Average 286.77K
- Market Capitalization 653.83B
- Employee 828
- CEO Mr. Chang-Kyun Kim
- Headquarters Seoul,KR
- IPO Date 2000-01-04
-
Website
https://shinpoong.co.kr 
Shin Poong Pharm.Co.,Ltd. manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products. It also provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; and over the counter products. The company also exports its products to approximately 50 countries. Shin Poong Pharm.Co.,Ltd. was founded in 1962 and is headquartered in Seoul, South Korea.
